Shilgem 1g Injection (Gemcitabine Injection IP)

Shilgem 1g Injection contains gemcitabine, a cytotoxic antimetabolite chemotherapy medicine. After entering cells, it is converted into active metabolites that interfere with DNA synthesis and inhibit enzymes needed for DNA production, thereby slowing or stopping the multiplication of susceptible cancer cells.

Gemcitabine 1g Injection is used alone or in combination regimens for several solid tumors, including pancreatic, non-small-cell lung, bladder, breast, and ovarian cancers, depending on the clinical setting and local label. It is administered intravenously by trained healthcare professionals. Blood counts and organ function must be monitored because the gemcitabine 1g Injection can cause significant bone marrow suppression and, less commonly, serious lung, liver, kidney, or vascular complications.

Gemcitabine 1g Injection is used in established chemotherapy regimens for pancreatic adenocarcinoma, non-small-cell lung cancer, bladder cancer, breast cancer, and ovarian cancer. It may be used alone or with medicines such as cisplatin, carboplatin, paclitaxel, or other agents depending on the tumor and treatment line. The exact indication, dose, and schedule are protocol-specific. Oncologists consider disease stage, previous therapy, blood counts, liver and kidney function and overall fitness before each cycle. Gemcitabine 1g injection is also used in additional specialist protocols where supported by guidelines.

Gemcitabine 1g Injection is a nucleoside analogue antimetabolite. Inside cells it is converted to active metabolites that inhibit ribonucleotide reductase and become incorporated into DNA. This reduces the nucleotide pool required for DNA synthesis and causes masked chain termination, preventing effective DNA replication. Rapidly dividing cancer cells are especially affected, but normal bone-marrow cells can also be suppressed, making regular blood-count monitoring essential.

Evidence context: The studies below are pivotal or widely cited evidence supporting the gemcitabine 1g injection in major treatment settings. Trial results should not be interpreted as a guarantee of benefit for an individual patient, and exact eligibility must match the current approved indication and oncology guideline.

Shilgem 1g Injection may cause side effects, and their frequency varies by indication, dose, combination regimen, and patient population. The list below highlights clinically important effects rather than assigning a single percentage across different trials.

Common side effects

• Neutropenia / leukopenia
• Thrombocytopenia
• Anemia
• Nausea and vomiting
• Fever / flu-like symptoms
  
• Rash
  
• Raised liver enzymes
  
• Fatigue
  
• Serious side effects
  
• Severe infection
  
• Pneumonitis / pulmonary edema
  
• Hemolytic uremic syndrome
  
• Severe liver injury
  
• Capillary leak syndrome
  
• PRES

Gemcitabine injection is protocol dependent. Labelled schedules vary substantially by cancer and combination partner, for example, weekly dosing on specified days of a 21- or 28-day cycle. It is commonly infused over about 30 minutes; extending infusion time or increasing dosing frequency can increase toxicity. The 1 gm vial is a product presentation, not a standard patient dose. The oncologist determines the dose from body surface area, diagnosis, combination regimen, blood counts, and organ function.

Administration guidance: The Shilgem 1g Injection must be prepared and administered intravenously by trained healthcare professionals. The dose and treatment days depend on the cancer type and combination regimen. Infusion is commonly given over a defined period; unusually prolonged infusion can increase toxicity and should be avoided unless specifically part of a protocol. Blood counts are checked before treatment, and the dose may be delayed or reduced for cytopenias. Liver and kidney function may also be monitored. Do not self-administer. Report fever, breathing difficulty, unusual bleeding, reduced urine output, or severe swelling promptly.​

If a scheduled infusion is missed, contact the oncology unit. Do not change the chemotherapy calendar independently; the treatment team decides rescheduling based on the protocol and laboratory results.

CBC should be checked before each dose/cycle. Monitor liver and kidney function. Evaluate new respiratory symptoms promptly. Watch for haemolysis, thrombocytopenia, and renal impairment, suggesting HUS. Coordinate carefully with radiotherapy schedules.

Practical monitoring checklist

• Complete blood count (CBC) at the label/protocol-recommended intervals
  
• Liver function according to baseline risk and treatment label
  
• Renal function and hydration/renal toxicity assessment as clinically indicated
  

• FDA/EMA gemcitabine 200mg Injection prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209604s002lbl.pdf
  
• NCI Drug Dictionary: Gemcitabine Injection. https://www.cancer.gov/about-cancer/treatment/drugs/gemcitabinehydrochloride
  
• Relevant NCCN disease-specific chemotherapy protocols. https://www.nccn.org/guidelines/category_1​
  
• National library of medicine. Gemcitabine. https://pubmed.ncbi.nlm.nih.gov/9279506/​
  
• SpringerNature. Gemcitabine treatment. https://link.springer.com/article/10.1186/s12885-026-15836-3​